Amgen’s Myeloma Drug Reports Longer Survival (AMGN)

Share it with your friends Like

Thanks! Share it with your friends!


Amgen’s Myeloma Drug Reports Longer Survival (AMGN)
Nasdaq-listed Amgen Inc. (AMGN) announced that its key drug Kyprolis (carfilzomib) significantly enhanced the overall survival (OS) compared to Takeda Pharmaceutical
Co.’s Velcade (bortezomib) in a head-to-head phase 3 trial comparing the two therapies for treating relapsed or refractory multiple myeloma patients.
” said Dr. Meletios Dimopoulos, trial co-author and investigator.
that Based on these data, we now know that Kyprolis not only significantly extended progression-free survival compared to Velcade, but also overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma,
The earlier PFS data was the basis of Kyprolis securing approval in the U. S., European Union,
and other nations for treating multiple myeloma that has advanced after treatment with other drugs.
The existing prescription label of Kyprolis includes the PFS data about Kyprolis’ 18.7 months PFS compared to Velcade’s 9.4 months.
The ones who were administered Kyprolis plus a low dose of dexamethasone lived an average of 47.6
months, compared to 40 months survival period for those who were on Velcade plus dexamethasone.
The late stage trial comprised of 929 patients whose multiple myeloma had relapsed following earlier therapy.
The positive OS results add to the earlier published data that demonstrated Kyprolis’ supremacy over Velcade for progression-free survival (PFS).


Write a comment